Table 2.

Evolution of the consumption of considered strategic antibacterials for respiratory tract infections in the community in Navarre per quarters (DID and patients treated).

		1st Quarter			2nd Quarter			3rd Quarter			4th Quarter			p *
		2019	2021	Variation	2019	2021	Variation	2019	2021	Variation	2019	2021	Variation
J01CA04—Amoxicillin	DID	5.044	1.989	−61%	4.247	2.189	−48%	3.220	1.947	−40%	4.668	3.375	−28%	0.017
	Patients	23,571	8636	−63%	20,277	10,152	−50%	14,637	8889	−39%	22,833	16,544	−28%	0.013
J01CR02—Amoxicillin + clavulanic acid	DID	4.997	2.737	−45%	4.377	2.826	−35%	3.875	2.903	−25%	4.072	3.525	−13%	0.003
	Patients	17,761	10,264	−42%	15,867	10,851	−32%	14,274	11,205	−22%	15,520	13,678	−12%	0.003
J01DC02—Cefuroxime	DID	1.556	1.117	−28%	1.324	1.160	−12%	1.249	1.176	−6%	1.522	1.434	−6%	0.048
	Patients	6093	4389	−28%	5249	4604	−12%	4924	4732	−4%	6111	5871	−4%	0.042
J01FA10—Azithromycin	DID	1.525	0.513	−66%	1.165	0.533	−54%	0.894	0.474	−47%	1.338	1.054	−21%	0.044
	Patients	14,780	4158	−72%	11,336	4856	−57%	8388	4041	−52%	13,409	10,446	−22%	0.017
J01MA12—Levofloxacin	DID	1.099	0.384	−65%	0.765	0.371	−52%	0.550	0.367	−33%	0.688	0.587	−15%	0.022
	Patients	5787	1864	−68%	4068	1861	−54%	2799	1751	−37%	3757	3130	−17%	0.027

* Comparing periods pre-pandemic and pandemic. DID: Defined daily doses per 1000 inhabitants per day.